DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Adherence to PTH(1-84) Treatment (FP-002-IM)

Completed

Conditions: Clinical Use of PTH(1-84)

Interventions: Drug: Parathyroid Hormone (PTH) (1-84)

First Posted Date: 2007-05-25

Last Posted Date: 2014-05-28

Lead Sponsor: Takeda

Target Recruit Count: 1179

Registration Number: NCT00478569

Locations: 🇩🇰
Nycomed, Roskilde, Denmark

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Phase 2

Completed

Conditions: Esophagitis

Interventions: Drug: Lansoprazole
Drug: Ilaprazole

First Posted Date: 2007-05-09

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 831

Registration Number: NCT00471094

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Phase 4

Terminated

Conditions: Gastroesophageal Reflux Disease
Non-erosive Reflux Disease

Interventions: Drug: Pantoprazole

First Posted Date: 2007-03-21

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT00449813

Locations: 🇨🇭
Altana Pharma/Nycomed, Zürich, Switzerland

Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone and sulphonylurea
Drug: Pioglitazone and metformin

First Posted Date: 2007-03-20

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 326

Registration Number: NCT00449553

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Pioglitazone
Drug: Metformin
Drug: Placebo

First Posted Date: 2007-02-07

Last Posted Date: 2013-04-04

Lead Sponsor: Takeda

Target Recruit Count: 803

Registration Number: NCT00432276

Efficacy and Safety of Oral Febuxostat in Participants With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2007-02-01

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 2269

Registration Number: NCT00430248

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

Phase 4

Completed

Conditions: Chronic Insomnia

Interventions: Drug: Placebo
Drug: Ramelteon

First Posted Date: 2006-12-21

Last Posted Date: 2016-06-28

Lead Sponsor: Takeda

Target Recruit Count: 552

Registration Number: NCT00414102

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2006-11-03

Last Posted Date: 2013-03-27

Lead Sponsor: Takeda

Target Recruit Count: 655

Registration Number: NCT00395512

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: TAK-583
Drug: Placebo

First Posted Date: 2006-09-18

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 399

Registration Number: NCT00377598

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Type 2 Diabetes

Interventions: Drug: Pioglitazone and Azilsartan
Drug: Pioglitazone

First Posted Date: 2006-09-14

Last Posted Date: 2010-06-22

Lead Sponsor: Takeda

Target Recruit Count: 96

Registration Number: NCT00376181

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy